Latest news
Climb Bio (NASDAQ:CLYM) Is In A Good Position To Deliver On Growth Plans - simplywall.stsimplywall.st · Sat, 08 Aug 2026 13:38:44 GMTOppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - MoomooMoomoo · Sat, 08 Aug 2026 00:18:39 GMTCLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - BitgetBitget · Fri, 07 Aug 2026 11:54:35 GMTClimb Bio Releases Q2 2026 Financial Results - AlphaStreetAlphaStreet · Thu, 06 Aug 2026 18:45:04 GMTClimb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock TitanStock Titan · Thu, 06 Aug 2026 11:46:28 GMTClimb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock TitanStock Titan · Thu, 06 Aug 2026 11:35:35 GMTClimb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:19:18 GMTClimb Bio expects CLYM116 Phase 2 dosing to begin in Q3 - Stock TitanStock Titan · Thu, 06 Aug 2026 11:00:00 GMT